Close Menu

BioReference Laboratories

A study of 10 commercial labs offering NIPT in the US found that none followed all recommendations for reporting results and informing patients and providers.

BioReference Lab's GenPath division will notify treating oncologists when a genomic alteration is detected that matches an NCI-MATCH treatment arm.

Seventeen organizations don't support the Diagnostic Accuracy and Innovation Act as written and would like lawmakers to advance a CLIA-centric framework.


The partners are planning to conduct meta-analyses of shared exome datasets from patients with inherited neurological disorders.

Opko subsidiary Bio-Reference Laboratories is retiring GeneTests.org next month given the availability of the NIH-backed Genetic Testing Registry.

The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.

Under today's deal, all of UC Health's medical centers will work with GeneDx and have access to more than 400 of the firm's tests for rare hereditary disorders. 

Diaceutics will use the data to help its pharmaceutical industry clients speed their rollouts of new cancer drugs.

Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.

The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.

Pages

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.